Literature DB >> 27029927

Zika - another threat on the epidemiological map of the world.

Krzysztof Korzeniewski1, Dariusz Juszczak, Ewa Zwolińska.   

Abstract

Zika fever is an acute infectious disease caused by the Zika virus (ZIKV) of the Flaviviridae family and Flavivirus genus. It is transmitted by day-time active Aedes mosquitoes, and potentially by sexual contacts, blood transfusion, and from mother to foetus (resulting in microcephaly in a child). ZIKV was first isolated from a macaque monkey in the Zika forest in Uganda in 1947. The first case of the Zika fever in a human was recorded in Nigeria in 1954. Until 2007 only 14 cases of the disease were confirmed worldwide. In 2007, there was an outbreak of the Zika fever in Micronesia (Yap Island) with an estimated 5,000 cases. Between 2013 and 2015 a further outbreak of the disease occurred in the Pacific islands: in French Polynesia, New Caledonia, Cook Islands, Easter Island, and Solomon Islands. In 2015, the Zika fever spread to Brazil and more than 20 other countries in the South and Central America. Until March 2016, an estimated 1.6 million autochthonous cases of Zika have been reported globally, with approximately 1.5 million cases recorded in Brazil. Typically, 80% of Zika infections are asymptomatic. The most common symptoms of the disease include fever, maculopapular rash, muscle and joint pain, conjunctivitis. Zika fever can be diagnosed on the basis of clinical signs (it must be differentiated from dengue, chikungunya), ZIKV identification is also possible by the application of polymerase chain reaction in acutely ill patients and the detection of specific IgM and IgG antibodies to ZIKV. Until today, there is no effective antiviral treatment or an effective vaccine against Zika fever (in case of an infection only symptomatic treatment is applied). In August 2016 in Rio de Janeiro (Brazil) Summer Olympic Games will take place, attracting thousands of athletes and spectators. The fight against the Zika fever and the race against time have gained momentum.

Entities:  

Keywords:  Zika virus; clinical symptoms; epidemiology; prevention

Mesh:

Year:  2016        PMID: 27029927     DOI: 10.5603/IMH.2016.0007

Source DB:  PubMed          Journal:  Int Marit Health        ISSN: 1641-9251


  5 in total

1.  Structural view of the helicase reveals that Zika virus uses a conserved mechanism for unwinding RNA.

Authors:  Lei Li; Jin Wang; Zhihui Jia; Neil Shaw
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2018-03-22       Impact factor: 1.056

2.  A Sensitive Method for Detecting Zika Virus Antigen in Patients' Whole-Blood Specimens as an Alternative Diagnostic Approach.

Authors:  Fok-Moon Lum; Cui Lin; Olga Y Susova; Teck-Hui Teo; Siew-Wai Fong; Tze-Minn Mak; Linda Kay Lee; Chia-Yin Chong; David C B Lye; Raymond T P Lin; Andres Merits; Yee-Sin Leo; Lisa F P Ng
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

3.  Knowledge, Awareness, and Perception of Community Pharmacists to Zika Virus Infection in Klang Valley, Malaysia.

Authors:  Kah Yee Lim; Hong-Wai Tham
Journal:  Health Serv Insights       Date:  2020-05-28

4.  Immunological observations and transcriptomic analysis of trimester-specific full-term placentas from three Zika virus-infected women.

Authors:  Fok-Moon Lum; Vipin Narang; Susan Hue; Jie Chen; Naomi McGovern; Ravisankar Rajarethinam; Jeslin Jl Tan; Siti Naqiah Amrun; Yi-Hao Chan; Cheryl Yp Lee; Tze-Kwang Chua; Wearn-Xin Yee; Nicholas Kw Yeo; Thiam-Chye Tan; Xuan Liu; Sam Haldenby; Yee-Sin Leo; Florent Ginhoux; Jerry Ky Chan; Julian Hiscox; Chia-Yin Chong; Lisa Fp Ng
Journal:  Clin Transl Immunology       Date:  2019-11-05

5.  Zika Virus Infection Preferentially Counterbalances Human Peripheral Monocyte and/or NK Cell Activity.

Authors:  Fok-Moon Lum; David Lee; Tze-Kwang Chua; Jeslin J L Tan; Cheryl Y P Lee; Xuan Liu; Yongxiang Fang; Bernett Lee; Wearn-Xin Yee; Natasha Y Rickett; Po-Ying Chia; Vanessa Lim; Yee-Sin Leo; David A Matthews; Julian A Hiscox; Lisa F P Ng
Journal:  mSphere       Date:  2018-03-28       Impact factor: 4.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.